Literature DB >> 33654514

[Acute prostatitis associated with noncancerous prostate at the Lubumbashi University Clinics: epidemioclinical and therapeutic features].

Manix Ilunga Banza1, Trésor Kibangula Kasanga1, Augustin Kibonge Mukakala1,2, Yannick Tietie Ben N'dwala1, Christelle Ngoie Ngoie1, Vincent De Paul Kaoma Cabala1, Néron Tapenge Shutsha1, Lire Ipani Lire1, Eric Wakunga Unen1, Nathalie Dinganga Kapessa1.   

Abstract

INTRODUCTION: acute prostatitis is a common urological condition. The purpose of this study was to analyze the epidemioclinical features and therapy of acute prostatitis associated with noncancerous prostate at the Lubumbashi University Clinics.
METHODS: we conducted a descriptive cross-sectional and retrospective study of a series of 25 patients with documented acute prostatitis and treated at the Lubumbashi University Clinics over a period of four years, from 2015 to 2018. All patients with prostate cancer were excluded from our study. Data were collected via a survey form based on different study parameters divided into 3 categories, namely epidemiological data including age, study period, residence, clinical data with subjective signs, objective signs, general status, findings on rectal examination as well as paramedical data divided into laboratory and imaging tests.
RESULTS: acute prostatitis associated with noncancerous prostate accounted for 1.27% of all surgical diseases and 7.66% in urology. The most affected age group was 19-37 years (64% of cases), mean age was 33.16±2.4 years. Seventeen patients (68%) were followed up in outpatient clinics and 8 (32%) in hospital. Clinically, fever above 38.5°C was found in 15 patients (60%), dysuria in 11 patients (44%), acute urinary retention in 3 patients (12%), burning during urination in 8 patients (32%), pain syndrome in 21 patients (84%), tender prostate on rectal examination in 18 patients (72%). Ultrasound was the only examination performed in 16 patients (64%). Biologically, assessment of inflammation was performed almost systematically in all patients (100%) including complete blood count (CBC), sedimentation rate (SR), C reactive protein (CRP) levels; blood culture was performed in 4 patients (16%), three of whom had positive blood culture. All patients underwent cytobacteriological examination of the urine or prostatic secretions collected by prostate massage. Urine culture was sterile in 6 patients (24%) and positive in 19 patients (76%). Escherichia coli was the most common germ in 16 out of a total of 19 patients (84.21%). All patients received rectal anti-inflammatory drugs. Fluoroquinolones were the most used antibiotics in 18 patients (64%), twelve of whom received antibiotics as monotherapy. Six out of 25 (24%) cases were associated with orchiepididymitis. The lenght of treatment ranged from 2 to 4 weeks, with either sterilization in secretions or urine or disappearance of leukocyturia as the criteria for treatment discontinuation. Thus, out of 19 patients with positive culture on admission, 14 underwent a second culture (73.68%) at 2 weeks of treatment, three of whom (12%) still had positive test and had to undergo a third culture 4 weeks after they had started treatment. Patient's course was good in 22 cases (88%) with complete clinical and biological remission; three patients (12%) persisted in symptoms which became chronic; no patients had prostatic abscess.
CONCLUSION: acute prostatitis associated with noncancerous prostate is a really worrying urological, nosologic condition whose management must be rigorous, especially in people at risk, namely those with intense sexual behaviour. Endorectal ultrasound and prostate massage should be integrated into patient care at the Lubumbashi University Clinics. Copyright: Manix Ilunga Banza et al.

Entities:  

Keywords:  Prostatitis; acute; epidemiology; noncancerous

Mesh:

Substances:

Year:  2020        PMID: 33654514      PMCID: PMC7881926          DOI: 10.11604/pamj.2020.37.290.21260

Source DB:  PubMed          Journal:  Pan Afr Med J


  47 in total

Review 1.  [Bacteriologic diagnosis and antibiotic therapy of urinary tract infections].

Authors:  François Caron
Journal:  Rev Prat       Date:  2003-10-31

Review 2.  [Acute and chronic prostatitis, how will we manage it ten years from now?].

Authors:  B Lobel
Journal:  Rev Med Suisse       Date:  2006-12-06

Review 3.  [Acute prostatitis].

Authors:  F Bruyère; G Cariou; J-P Boiteux; A Hoznek; J-P Mignard; L Escaravage; L Bernard; A Sotto; C-J Soussy; P Coloby
Journal:  Prog Urol       Date:  2008-03       Impact factor: 0.915

Review 4.  Acute Bacterial Prostatitis: Diagnosis and Management.

Authors:  Timothy J Coker; Daniel M Dierfeldt
Journal:  Am Fam Physician       Date:  2016-01-15       Impact factor: 3.292

Review 5.  [From cystitis to bacterial prostatitis: experience with levofloxacin].

Authors:  Vincenzo Mirone
Journal:  Infez Med       Date:  2009-12

6.  Acute bacterial prostatitis after transrectal ultrasound-guided prostate biopsy: epidemiological, bacteria and treatment patterns from a 4-year prospective study.

Authors:  Alexandre Campeggi; Idir Ouzaid; Evanguelos Xylinas; Philippe Lesprit; Andras Hoznek; Dimitri Vordos; Claude-Clément Abbou; Laurent Salomon; Alexandre de la Taille
Journal:  Int J Urol       Date:  2013-08-01       Impact factor: 3.369

7.  Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men.

Authors:  S Holmäng; P Mårin; G Lindstedt; H Hedelin
Journal:  Prostate       Date:  1993       Impact factor: 4.104

Review 8.  Bacterial Prostatitis: Bacterial Virulence, Clinical Outcomes, and New Directions.

Authors:  John N Krieger; Praveen Thumbikat
Journal:  Microbiol Spectr       Date:  2016-02

Review 9.  Bacterial prostatitis.

Authors:  Bradley C Gill; Daniel A Shoskes
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

Review 10.  Diagnosing the prostatitis patient: the dilemma continues.

Authors:  Jeannette M Potts
Journal:  Curr Urol Rep       Date:  2002-08       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.